Do patients diagnosed with EGFR-mutant non–small cell lung cancer (NSCLC) receiving osimertinib have higher cancer therapy–related cardiac events (CTRCEs) compared with those receiving other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs)? This evidence concerns the gene EGFR and non-small cell lung carcinoma.